BHVN Stock Overview
Focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Biohaven Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.26 |
| 52 Week High | US$62.21 |
| 52 Week Low | US$26.80 |
| Beta | 3.79 |
| 1 Month Change | -20.47% |
| 3 Month Change | -21.07% |
| 1 Year Change | -9.53% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 396.71% |
Recent News & Updates
Recent updates
Biohaven's Revenue Path: SCA And Obesity Therapies
Nov 29Biohaven: A Complicated Tale
Oct 11Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Shareholder Returns
| BHVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.7% | -3.6% | -2.4% |
| 1Y | -9.5% | -2.7% | 23.3% |
Return vs Industry: BHVN underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: BHVN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| BHVN volatility | |
|---|---|
| BHVN Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BHVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BHVN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 239 | Vlad Coric | www.biohaven.com |
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
Biohaven Ltd. Fundamentals Summary
| BHVN fundamental statistics | |
|---|---|
| Market cap | US$3.67b |
| Earnings (TTM) | -US$804.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs BHVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$804.34m |
| Earnings | -US$804.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BHVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biohaven Ltd. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |